Hepatitis B virus reactivation after heart transplant: Incidence and clinical impact
Autor: | Martina Vitrone, Emanuele Durante-Mangoni, Ciro Maiello, Domenico Iossa, Luca Rinaldi, Roberto Andini, Rosa Molaro, Pia Clara Pafundi, Rosa Zampino, Antonio Parrella, Enrico Ragone |
---|---|
Přispěvatelé: | Vitrone, Martina, Iossa, Domenico, Rinaldi, Luca, Pafundi, Pia Clara, Molaro, Rosa, Parrella, Antonio, Andini, Roberto, Ragone, Enrico, Maiello, Ciro, Zampino, Rosa, Durante-Mangoni, Emanuele |
Rok vydání: | 2017 |
Předmět: |
Adult
Male medicine.medical_specialty HBsAg Occult hepatitis B infection (OBI) medicine.medical_treatment Hepatitis B reactivation 030230 surgery medicine.disease_cause Polymerase Chain Reaction Gastroenterology Cohort Studies Immunocompromised Host 03 medical and health sciences Liver disease 0302 clinical medicine Virology Internal medicine Genotype medicine Humans Aged Hepatitis B virus business.industry Virological event Incidence Incidence (epidemiology) Mortality rate virus diseases Immunosuppression Middle Aged Hepatitis B medicine.disease digestive system diseases Infectious Diseases Liver Heart failure Immunology Heart Transplantation Heart transplant Female Virus Activation 030211 gastroenterology & hepatology business Immunosuppressive Agents Follow-Up Studies |
Zdroj: | Journal of Clinical Virology. 96:54-59 |
ISSN: | 1386-6532 |
DOI: | 10.1016/j.jcv.2017.09.011 |
Popis: | Background Occult hepatitis B infection consists of persistence of HBV genomes in hepatocytes,absence of serum HBsAg, low/undetectable serum HBVDNA. Reactivation of HBV infection may occur during immunosuppression, but few data are available in heart transplant. Objectives We followed-up heart recipients with or without markers of previous HBV infection,evaluating prevalence of HBV markers, incidence of HBV reactivation and its virological and clinical features. Study design Heart failure patients listed for heart transplant (2007–2013) were screened for current or past HBV infection. Transplanted patients with past HBV infection (anti-HBc+/±anti-HBs+/HBVDNA−) were followed up as cases, and an equal number of HBV negative patients as controls. Virological reactivation was detected by standard real-time and home-made highly sensitive PCR (surface/core HBVDNA regions). Clinical status and progression were assessed by liver histology, ultrasound or elastography. Results 67 patients underwent heart transplant, including 4 (5.9%) HBsAg+ subjects. Cases were 11/67 (16.4%). During a median follow-up of 30 months, only one of these 11 patients presented viral reactivation (HBVDNA 209 IU/mL) at month 22, and started antiviral treatment. Four other recipients showed virological events of uncertain significance (sensitive PCR-only intermittently positive). Clinical signs of liver disease were observed in only one case at the last follow-up. A nonsignificant difference in survival was observed between cases and all other heart recipients without prior HBV contact (death rate 5/11 vs 15/52, respectively; p = 0.097). Conclusions HBV genotypic reactivation in HBsAg−/anti-HBc+/HBVDNA− heart recipients is uncommon. Virological events of uncertain significance occur more frequently; their clinical impact seems to be negligible. |
Databáze: | OpenAIRE |
Externí odkaz: |